Terms: = Pancreatic cancer AND BCL9L, BCL9-2, 283149, ENSG00000186174, DLNB11
5 results:
1. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review).
Katoh M
Int J Mol Med; 2018 Aug; 42(2):713-725. PubMed ID: 29786110
[TBL] [Abstract] [Full Text] [Related]
2. Role of bcl9l in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract] [Full Text] [Related]
3. bcl9l expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.
Hallas C; Phillipp J; Domanowsky L; Kah B; Tiemann K
BMC Cancer; 2016 Aug; 16():648. PubMed ID: 27539223
[TBL] [Abstract] [Full Text] [Related]
4. FGF signaling inhibitor, SPRY4, is evolutionarily conserved target of WNT signaling pathway in progenitor cells.
Katoh Y; Katoh M
Int J Mol Med; 2006 Mar; 17(3):529-32. PubMed ID: 16465403
[TBL] [Abstract] [Full Text] [Related]
5. Identification and characterization of human bcl9l gene and mouse bcl9l gene in silico.
Katoh M; Katoh M
Int J Mol Med; 2003 Oct; 12(4):643-9. PubMed ID: 12964048
[TBL] [Abstract] [Full Text] [Related]
